Gene Expression Analysis in Human Breast Cancer Associated Blood Vessels

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Jones, Dylan T ^a   Lechertier, Tanguy ^a   Mitter, Richard ^b   Herbert, John M J ^c   Bicknell, Roy ^c   Jones, J Louise ^a   Li, Ji Liang ^d   Buffa, Francesca ^d   Harris, Adrian L ^d   Hodivala Dilke, Kairbaan ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFT1 GENE; ANGIOGENESIS; ARTICLE; BIOTINYLATION; BREAST CANCER; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEX B GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRON DEPLETION; MICROARRAY ANALYSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RRM2 GENE; TISSUE PREPARATION; UNINDEXED SEQUENCE; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; AORTA, THORACIC; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867016983     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044294     Document Type: Article

References (71)

1. Kerbel R, Folkman J, (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
2. Ellis LM, Hicklin DJ, (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W, (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
4. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
5. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, et al. (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25: 852-861.
6. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, et al. (2004) Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165: 601-608.
7. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, et al. (2004) Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 64: 7857-7866.
8. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. (2000) Genes expressed in human tumor endothelium. Science 289: 1197-1202.
9. Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, et al. (2008) Molecular characterization of human breast tumor vascular cells. Am J Pathol 172: 1381-1390.
10. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
11. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, et al. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. The Journal of clinical investigation 102: 430-437.
12. Pasqualini R, Koivunen E, Ruoslahti E, (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nature biotechnology 15: 542-546.
13. Arap W, Pasqualini R, Ruoslahti E, (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
14. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nature medicine 5: 1032-1038.
15. Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, et al. (2004) Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 23: 2564-2575.
16. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, et al. (2004) Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64: 8558-8565.
17. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, et al. (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23: 1377-1391.
18. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, et al. (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65: 2170-2178.
19. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66: 4636-4644.
20. Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, et al. (2006) Gene expression profiling and clinical outcome in breast cancer. OMICS 10: 429-443.
21. Guo W, Jiang YG, (2009) Current gene expression studies in esophageal carcinoma. Curr Genomics 10: 534-539.
22. Ganguly A, Shields CL, (2010) Differential gene expression profile of retinoblastoma compared to normal retina. Molecular vision 16: 1292-1303.
23. Miecznikowski JC, Wang D, Liu S, Sucheston L, Gold D, (2010) Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways. BMC Cancer 10: 573.
24. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, et al. (2003) Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22: 2192-2205.
25. Wu M, Han L, Shi Y, Xu G, Wei J, et al. (2010) Development and characterization of a novel method for the analysis of gene expression patterns in lymphatic endothelial cells derived from primary breast tissues. Journal of cancer research and clinical oncology 136: 863-872.
26. Wu MS, Lin YS, Chang YT, Shun CT, Lin MT, et al. (2005) Gene expression profiling of gastric cancer by microarray combined with laser capture microdissection. World J Gastroenterol 11: 7405-7412.
27. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Conejo-Garcia JR, et al. (2006) Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther 5: 635-642.
28. Sugiyama Y, Sugiyama K, Hirai Y, Akiyama F, Hasumi K, (2002) Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol 117: 109-116.
29. Pagedar NA, Wang W, Chen DH, Davis RR, Lopez I, et al. (2006) Gene expression analysis of distinct populations of cells isolated from mouse and human inner ear FFPE tissue using laser capture microdissection-a technical report based on preliminary findings. Brain Res 1091: 289-299.
30. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, et al. (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124.
31. Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, et al. (2005) Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18: 143-152.
32. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC molecular biology 7: 3.
33. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
34. Team RDC (2010) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0.
35. Smyth GK (2005) Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor: 397-420.
36. Hochberg Y, Benjamini Y, (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
37. Herbert JM, Stekel D, Sanderson S, Heath VL, Bicknell R, (2008) A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics 9: 153.
38. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
39. Nicosia RF, Ottinetti A, (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26: 119-128.
40. Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, et al. (2010) Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 465: 813-817.
41. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, et al. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15: 392-400.
42. Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, et al. (2009) CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast cancer research: BCR 11: R1.
43. Li W, Yang D, Wang S, Guo X, Lang R, et al. (2011) Increased expression of CD146 and microvessel density (MVD) in invasive micropapillary carcinoma of the breast: Comparative study with invasive ductal carcinoma-not otherwise specified. Pathology, research and practice 207: 739-746.
44. Perlmutter MA, Best CJ, Gillespie JW, Gathright Y, Gonzalez S, et al. (2004) Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens. J Mol Diagn 6: 371-377.
45. Weng J, Wang J, Hu X, Wang F, Ittmann M, et al. (2006) PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer 118: 1471-1480.
46. Zhang K, Hu S, Wu J, Chen L, Lu J, et al. (2009) Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 8: 11.
47. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, et al. (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. British journal of cancer 104: 599-604.
48. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, et al. (2009) Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 20: 393-394.
49. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, et al. (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clinical breast cancer 11: 82-92.
50. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
51. Pusztaszeri MP, Seelentag W, Bosman FT, (2006) Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 54: 385-395.
52. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, et al. (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179: 80-88.
53. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T, (1996) Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 78: 226-231.
54. DeYoung BR, Swanson PE, Argenyi ZB, Ritter JH, Fitzgibbon JF, et al. (1995) CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. J Cutan Pathol 22: 215-222.
55. Singh R, Maganti RJ, Jabba SV, Wang M, Deng G, et al. (2005) Microarray-based comparison of three amplification methods for nanogram amounts of total RNA. American journal of physiology Cell physiology 288: C1179-1189.
56. Fakhrejahani E, Toi M, (2012) Tumor angiogenesis: pericytes and maturation are not to be ignored. Journal of oncology 2012: 261750.
57. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D, (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295.
58. Nordlund P, Reichard P, (2006) Ribonucleotide reductases. Annu Rev Biochem 75: 681-706.
59. Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, et al. (1985) Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 260: 9114-9116.
60. Bladon MT, (1981) The expression of hex A and hex B isozymes of hexosaminidase in parental and experimental human fibroblast cells and their components. Biochem Genet 19: 971-986.
61. Slevin M, Kumar S, He X, Gaffney J, (1999) Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. Int J Cancer 82: 412-423.
62. Lang Z, Guerrera M, Li R, Ladisch S, (2001) Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun 282: 1031-1037.
63. Liu Y, McCarthy J, Ladisch S, (2006) Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res 66: 10408-10414.
64. Mukherjee P, Faber AC, Shelton LM, Baek RC, Chiles TC, et al. (2008) Ganglioside GM3 suppresses the pro-angiogenic effects of vascular endothelial growth factor and ganglioside GD1A. J Lipid Res.
65. Dorniak P, Bazer FW, Wu G, Spencer TE (2012) Conceptus-Derived Prostaglandins Regulate Endometrial Function in Sheep. Biology of reproduction.
66. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, et al. (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Molecular cancer therapeutics 8: 1867-1877.
67. Ghosh SK, Gadiparthi L, Zeng ZZ, Bhanoori M, Tellez C, et al. (2002) ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. J Biol Chem 277: 21325-21331.
68. Laag E, Majidi M, Cekanova M, Masi T, Takahashi T, et al. (2006) NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer 119: 1547-1552.
69. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, et al. (2000) Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 19: 2721-2730.
70. Rikitake Y, Hirata K, Kawashima S, Takeuchi S, Shimokawa Y, et al. (2001) Signaling mechanism underlying COX-2 induction by lysophosphatidylcholine. Biochem Biophys Res Commun 281: 1291-1297.
71. Wu G, Luo J, Rana JS, Laham R, Sellke FW, et al. (2006) Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69: 512-519.